Skip to main content

Table 1 Baseline Characteristics during Index hospitalization and follow-up

From: The use of enoxaparin as bridge to therapeutic INR after LVAD implantation

  LMWH Index
N = 43
UFH Index
N = 207
P LMWH follow-up
N = 67
UFH follow-up
N = 177
P
Demographics
Age (SD) 51.9 (15.3) 56.1 (12.0) 0.02 52.7 (13.8) 56.6 (12.0) 0.02
Males (%) 29 (67.4) 170 (82.1) 0.03 58 (74.4) 141 (82) 0.17
Race (%)    0.03    0.001
 Caucasian 28 (65.1) 167 (80.7)   50 (64.1) 145 (84.3)  
 African American 13 (30.2) 39 (18.8)   26 (33.3) 26 (15.1)  
 Others 2 (4.7) 1 (0.5)   2 (2.6) 1 (0.6)  
Type of LVAD (%)    0.13    0.07
 HeartWare 18 (41.9) 84 (40.6)   36 (46.2) 66 (38.4)  
 HeartMate II 17 (39.5) 52 (25.1)   25 (32.1) 44 (25.6)  
 HeartMate III 8 (18.6) 71 (34.3)   17 (21.8) 62 (36.1)  
INTERMACS classification (%)    0.55    0.18
 INTERMACS 1 7 (16.3) 33 (15.9)   11 (14.) 29 (16.9)  
 INTERMACS 2 13 (30.2) 40 (19.3)   24 (30.8) 29 (16.9)  
 INTERMACS 3 17 (39.5) 110 (53.1)   37 (47.4) 90 (52.3)  
 INTERMACS 4–7 6 (14.0) 24 (12.0)   6 (7.7) 24 (14.0)  
Comorbidities (%)       
 Cardiomyopathy    0.32    0.38
  Ischemic 17 (39.5) 99 (47.8)   33 (42.3) 83 (48.3)  
  Non-ischemic 26 (60.5) 108 (52.2)   45 (57.7) 89 (51.7)  
CAD 20 (46.5) 75 (36.2) 0.21 34 (44.0) 61 (35.5) 0.22
Prior stroke 7 (16.3) 30 (15.0) 0.76 14 (18.0) 23 (13.34) 0.35
CKD 18 (42.0) 33 (16.0) < 0.01 30 (38.5) 21 (12.2) < 0.01
Atrial fibrillation    0.005    < 0.01
 Paroxysmal 7 (16.3) 85 (41.1)   16 (20.5) 76 (44.2)  
 Permanent 3 (6.9) 5 (6.9)   6 (7.7) 2 (1.2)  
Hypertension 29 (67.4) 128 (61.8) 0.49 55 (70.5) 102 (59.3) 0.09
Diabetes mellitus 18 (41.9) 102 (49.3) 0.38 32 (41.0) 88 (51.2) 0.14
Obesity 11 (25.6) 80 (38.8) 0.10 27 (34.6) 64 (37.4) 0.67
OSA 9 (20.9) 44 (21.4) 0.95 23 (30.0) 30 (17.5) 0.03
  1. CAD Coronary Artery Disease, CKD Chronic Kidney Disease, LVAD Left Ventricular Assist Device, OSA Obstructive Sleep Apnea